Cerebro-spinal fluid ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04798651 (ClinicalTrials.gov)	September 30, 2021	11/3/2021	Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis	Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis	Multiple Sclerosis;Clinically Isolated Syndrome	Biological: blood sample;Biological: cerebro-spinal fluid	University Hospital, Bordeaux	University of Bordeaux	Recruiting	18 Years	N/A	All	150	N/A	France
2	EUCTR2014-005493-11-FR (EUCTR)	31/08/2015	15/03/2018	Study the action of a single dose of intrathecally-infused rituximab upon cerebro-spinal fluid (CSF) biological targets, assuming that a definitive action upon CSF biological targets would be strongly predictive of a delayed clinical action in patients with Progressive Multiple Sclerosis.	Intrathecal Rituximab in Progressive Multiple Sclerosis - EFFRITE	Patients included in our study suffer from a progressive form of Multiple sclerosis and will be treated by intravenous and intrathecal rituximab, with intravenous methylprednisolone.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Méthylprednisolone Mylan Product Name: méthylprednisolone Trade Name: Mabthera Product Name: rituximab Trade Name: Mabthera Product Name: rituximab	Centre Hospitalier de Pau	NULL	Not Recruiting			Female: yes Male: yes	12	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	France